Hypoxemia

Polarean’s Xenon MRI to be Featured at Upcoming ATS 2024 Conference

Retrieved on: 
Mercoledì, Maggio 8, 2024
Hypoxemia, Supplement, Pulmonology, Patient, Adolescence, Inhalation, ATS, Euphoria, Adrenal insufficiency, Cystic fibrosis, Dizziness, AIM, Oxygen saturation (medicine), Doctor of Philosophy, Conference, Research, Bronchopulmonary dysplasia, Radiation-induced lung injury, Heart rate, Ageing, Transience, Headache, RIS, MRI, Magnetic resonance imaging, Hypoesthesia, Government, Asthma, Risk, COVID-19, Orthostatic hypertension, COPD, Medical imaging

The summit is scheduled to take place on May 17th-18th in San Diego, CA, at the Manchester Grand Hyatt San Diego.

Key Points: 
  • The summit is scheduled to take place on May 17th-18th in San Diego, CA, at the Manchester Grand Hyatt San Diego.
  • The Respiratory Innovation Summit, a premier event in the field of pulmonary medicine, unites innovators, investors, clinicians, and advocacy groups.
  • After the dynamic discussions of the Respiratory Innovation Summit, Polarean eagerly anticipates further collaboration within the pulmonary medicine community at the 2024 ATS International Conference, held from May 19th to 22nd.
  • Christopher von Jako, PhD, CEO of Polarean, said: “The Respiratory Innovation Summit and the ATS annual conference serve as invaluable venues to spotlight our Xenon MRI platform, especially to those enthusiastic about fostering collaborative partnerships.

New Study Finds Significant Correlation Between Masimo ORi™ and Arterial Partial Pressure of Oxygen During One-Lung Ventilation

Retrieved on: 
Lunedì, Dicembre 11, 2023
Biotechnology, Surgery, Health, Pharmaceutical, Health Technology, Odds ratio, Samsung Medical Center, De novo, Blood, OLV, Sungkyunkwan University, Hypoxemia, Risk, MASI, Patient, Multimedia, Journal, FDA, Hyperoxia, Oxygen, Blood gas tension, Perioperative, Ori, Oxygen saturation (medicine), Receiver operating characteristic, Medical device, Medical imaging, Anesthesia, ROC

ORi is trended continuously with SpO2 as a unit-less index between 0.00 and 1.00 to extend the visibility of the patient oxygenation beyond SpO2 under supplemental oxygen.

Key Points: 
  • ORi is trended continuously with SpO2 as a unit-less index between 0.00 and 1.00 to extend the visibility of the patient oxygenation beyond SpO2 under supplemental oxygen.
  • During anesthesia, ORi was monitored using Masimo RD rainbow SET® Pulse CO-Oximetry sensors, and blood gas analysis was performed 15 minutes after OLV was initiated.
  • Of the 11 potential predictors for PaO2
  • The researchers concluded, “ORi values during one-lung ventilation were significantly correlated with PaO2 measured simultaneously.

WPI Researcher Leads Project To Develop Oxygen Sensor for Premature Infants of Color

Retrieved on: 
Martedì, Novembre 14, 2023
Hardware, Manufacturing, Technology, University, Education, Medical Devices, Baby, Maternity, Science, Biotechnology, Software, Consumer, Health, Mobile, Wireless, Engineering, Research, Carbon, COPD, Biomedical engineering, Pediatrics, White, National Science Foundation, Hypoxemia, Risk, Tissue, Patient, Michigan State University, Multimedia, Computer engineering, COVID-19, Blood, Electricity, Periodic breathing, NIH, WPI, Worcester Polytechnic Institute, Oxygen, Chronic obstructive pulmonary disease, University of Massachusetts, Hospital, Skin, Failure, Bangladesh Technical Education Board, Asthma, Patent, Nursing, Medical imaging

“Premature infants are at risk of respiratory distress, and oxygen monitoring is critical to their care so that they can leave hospitals and go home,” Guler said.

Key Points: 
  • “Premature infants are at risk of respiratory distress, and oxygen monitoring is critical to their care so that they can leave hospitals and go home,” Guler said.
  • “Some tools widely used at home to monitor oxygenation, however, do not accurately measure oxygen levels in infants with pigmented skin tones.
  • A separate study of 294 premature infants showed that pulse oximetry consistently underestimated oxygen levels and hypoxemia, or abnormally low oxygen levels, in Black infants compared to White infants .
  • In addition, Guler said, pulse oximetry fails to detect excessive oxygenation, or oxygen poisoning, in infants who receive oxygen therapy.

Polarean Partners with VIDA to Streamline Adoption of Advanced MRI of the Lungs

Retrieved on: 
Venerdì, Settembre 8, 2023
Xenon, Risk, Partnership, Radiation, Inhalation, Transience, AIM, Doctor of Philosophy, Supplement, Clinical trial, Hypoesthesia, Research, Biomarker, VIDA, MRI, Magnetic resonance imaging, Dizziness, Severe cutaneous adverse reactions, Oxygen saturation (medicine), Patient, Acquisition, Physician, Algorithm, Euphoria, Ageing, Hypoxemia, Heart rate, Headache, Adolescence, Medical imaging, Adult

The companies are partnering to develop solutions that further enable the Polarean xenon 129 MRI platform to accelerate clinical and research use.

Key Points: 
  • The companies are partnering to develop solutions that further enable the Polarean xenon 129 MRI platform to accelerate clinical and research use.
  • “Furthermore, this partnership perfectly aligns with our objective of extending the reach of XENOVIEW™ MRI, to provide tools to physicians that treat patients suffering from chronic lung disease.”
    “VIDA and Polarean are natural partners.
  • Since the technology is based on MRI, it does not expose patients to any ionizing radiation and its associated risks.
  • The dose of XENOVIEW, created through the Polarean HPX hyperpolarization system, is administered in a single 10-15 second breath-hold MRI procedure.

Biophytis To Present Positive Results of Phase 2-3 COVA Study At ERS 2023 21st Lung Science Conference

Retrieved on: 
Giovedì, Marzo 16, 2023
Conference, MD, Hospital, Trial of the century, Hypoxemia, Rio Preto, Patient, European Respiratory Society, LSC, COVID-19, Ageing, Respiratory failure, Safety, CET, Therapy, Euronext Growth, Pharmaceutical industry, Paulo

The ERS Lung Science Conference (LSC) is at the forefront of basic and translational respiratory science and is an essential event for all respiratory researchers.

Key Points: 
  • The ERS Lung Science Conference (LSC) is at the forefront of basic and translational respiratory science and is an essential event for all respiratory researchers.
  • It offers a unique opportunity to present the results in front of well-recognized peers from across the globe.
  • Stanislas Veillet, CEO of Biophytis, said: "We are very excited to present these positive data to the scientific community.
  • We are looking forward to the interactions with the scientists from around the world attending this conference.”

Researchers Harness the Power of Masimo Root®’s Advanced Multimodal Monitoring Capabilities to Study the Impact of Different Ventilatory Strategies on Brain Oxygenation During Thoracoscopic Surgery

Retrieved on: 
Lunedì, Gennaio 23, 2023
Health Technology, Health, Surgery, Clinical Trials, Capnography, Mercury (element), Intensive care medicine, PACU, Brain, Journal, OLV, T2, Tanta University, King Fahd Medical City, VATS, HR, Patient, Hospital, MMSE, Temperature, EEG, Oxygen saturation (medicine), Risk, Psi, Heart rate, BP, NIRS, NIBP, Multimedia, MASI, Thermoregulation, Hypoxemia, Medical imaging, Aldrete, Group II intron

The technologies involved included O3® regional oximetry, capnography with NomoLine® sampling lines, SedLine® brain function monitoring, and multiple rainbow® Pulse CO-Oximetry measurements.

Key Points: 
  • The technologies involved included O3® regional oximetry, capnography with NomoLine® sampling lines, SedLine® brain function monitoring, and multiple rainbow® Pulse CO-Oximetry measurements.
  • They enrolled 70 patients, ages 18-65, undergoing elective VATS requiring OLV, between September 2021 and September 2022 at The King Fahd General Hospital, Jeddah.
  • In the left hemisphere, the difference became significant at T2, p = 0.09, and remained significant [T3-13], p
  • MMSE scores were significantly higher in Group II 3 hours after surgery (p = 0.0009), but not at 24 hours after surgery.

Biophytis announces positive final results of the phase 2-3 COVA study with Sarconeos (BIO101) in severe COVID-19

Retrieved on: 
Giovedì, Febbraio 2, 2023
Disease, News, Euronext Growth, EAP, PP, Kaplan–Meier estimator, CET, American Thoracic Society, Ageing, COVID-19, EUA, Intention-to-treat analysis, Trial of the century, Death, Safety, Risk, Vaccination, Severe acute respiratory syndrome coronavirus 2, CMA, ICU, Special access program, Therapy, Patient, ITT, Mortality, Male, Marketing authorisation, Protocol, Hypoxemia, Pharmaceutical industry

Biophytis announces today final results following the reintegration of data from 54 patients, among 233 patients treated, that were missing in the Top Line analysis released on September 7, 2022.

Key Points: 
  • Biophytis announces today final results following the reintegration of data from 54 patients, among 233 patients treated, that were missing in the Top Line analysis released on September 7, 2022.
  • Stanislas Veillet, CEO of Biophytis, said: " The COVA study is positive, with a statistically significant reduction of 44% in the risk of respiratory failure or early death, demonstrating the therapeutic potential of Sarconeos (BIO101) in the treatment of severe COVID-19.
  • This huge success is the result of Biophytis scientific excellence and hard work of the clinical and medical teams involved in the COVA clinical study in France, Belgium, the USA and in Brazil.
  • Biophytis is now initiating key regulatory activities to give access to Sarconeos (BIO101) to hospitalized patients with severe COVID-19 at risk of respiratory failure and death in 2023.

Beyond Cancer® Publishes Pre-Clinical Data in Cancer Cell International Demonstrating Its Tumor Ablation Method Utilizing Ultra-High Concentration Nitric Oxide (UNO) Induced a Systemic Response that Prevents Metastases

Retrieved on: 
Martedì, Dicembre 13, 2022
Associate, Neoplasm, Annual report, Security (finance), Atmosphere of Earth, Nitric oxide, MD, Toxicity, COVID-19, Policy, Wilms' tumor, Urinary tract infection, Div, Abscopal effect, Respiratory distress syndrome, Pulmonology, FDA, Safety, Cancer, Stanford University School of Medicine, Radiation, Manuscript, NO, Pulmonary hypertension, NTM, GNO, Kaplan–Meier estimator, Nontuberculous mycobacteria, Surgical oncology, UNO, Patient, Immunotherapy, CCI, APC, Hypoxemia, Death, Ultra, Mouse, B cell, Survival, Metastasis, Pharmaceutical industry, Vaccine, Medical imaging, Surgery

The data were published in an article entitled, “Gaseous Nitric Oxide Tumor Ablation Induces an Anti-Tumor Abscopal Effect,” in the peer-reviewed journal Cancer Cell International (“CCI”).

Key Points: 
  • The data were published in an article entitled, “Gaseous Nitric Oxide Tumor Ablation Induces an Anti-Tumor Abscopal Effect,” in the peer-reviewed journal Cancer Cell International (“CCI”).
  • “Beyond Cancer’s novel implementation of ultra-high concentrations of nitric oxide to treat solid tumors has repeatedly resulted in data demonstrating an immunostimulatory response,” stated Dr. Hila Confino, Chief Scientific Officer.
  • Two weeks post gas treatment, the tumors were resected and a week later a secondary tumor was induced in the contralateral flank.
  • In vitro murine data show that local tumor ablation with UNO stimulates an anti-tumor immune response in solid tumor cancer models.

Vapotherm Announces NYSE Continued Listing Standard Notice Related to Stock Price

Retrieved on: 
Martedì, Dicembre 6, 2022
Surgery, Medical Devices, Hospitals, Health, Medical Supplies, Security (finance), Breathe Me, Food, Calendar, VAPO, Regulation, Patient, Gas, Notice, NYSE, COVID-19, Failure, Hypoxemia, Food and Drug Administration, Regulation Fair Disclosure, Patent, Risk, Vapotherm

As set forth in the Notice, as of November 29, 2022, the 30-trading day average closing share price of the Companys common stock was $0.98 per share.

Key Points: 
  • As set forth in the Notice, as of November 29, 2022, the 30-trading day average closing share price of the Companys common stock was $0.98 per share.
  • As of December 5, 2022, the closing share price of the Companys common stock was $1.62 per share and the 30-trading day average closing share price of the Companys common stock was $1.01.
  • The Notice has no immediate impact on the listing of the Companys common stock, which will continue to trade on the NYSE during the applicable cure period, subject to all other listing requirements of the NYSE.
  • The .BC indicator will be removed at such time as the Company regains compliance with all continued listing standards.

Vapotherm Announces Amendment to Debt Agreement

Retrieved on: 
Martedì, Novembre 22, 2022
General Health, Health, Other Health, Medical Devices, Asset-backed security, SLR, Failure, PIK, Strike, Food and Drug Administration Amendments Act of 2007, Gas, VAPO, Patent, Adjustment, Thirty-third Amendment of the Constitution of Ireland, NYSE, Food, Finance Secretary (India), Security agreement, Security (finance), Breathe Me, Food and Drug Administration, Second Amendment to the United States Constitution, Hypoxemia, Term, Growth, LIBOR, COVID-19, Loan, Regulation, Regulation Fair Disclosure, Amendment, Security, Patient, Vapotherm

3 to its Loan and Security Agreement (the Third Amendment, with SLR Investment Corp. (SLR), as Collateral Agent, and the lenders party thereto.

Key Points: 
  • 3 to its Loan and Security Agreement (the Third Amendment, with SLR Investment Corp. (SLR), as Collateral Agent, and the lenders party thereto.
  • The Loan and Security Agreement matures on February 1, 2027 (the Maturity Date).
  • Vapotherm, Inc. (NYSE: VAPO) is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA.
  • Vapotherm high velocity therapy is mask-free noninvasive ventilatory support and is a front-line tool for relieving respiratory distressincluding hypercapnia, hypoxemia, and dyspnea.